http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2279159-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dee3727dba91e4e7aa3b26ce9efbcc21 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-147777 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C17-2632 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C17-263 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C17-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-18 |
| filingDate | 2009-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbae88aad51a70e95d019c5f663ddde1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8363998c7837c655b2898274009724e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ae6a0c80bd06303ef75c4de5c483928 |
| publicationDate | 2011-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2279159-A2 |
| titleOfInvention | 2'-halobiphenyl-4-yl intermediates in the synthesis of angiotensin ii antagonists |
| abstract | A process for obtaining 2'-halo-4-methylbiphenyls is described, which comprises reacting 4 halotoluene with a 1,2-dihalobenzene in the presence of elemental metal such as magnesium, lithium or zinc, wherein 0 to 0.9 molar, particularly 0 to 0.2 molar excess of 4-halotoluene in regard to 1,2-dihalobenzene is used, and arised organometal intermediates are quenched by elemental halogen. In addition, the coupling of arised 2'-halo-4-methylbiphenyls with 2-(1-propyl)-4-methyl-6-(1'-methylbenzimidazole-2-il)benzimidazole to afford 3'-(2'-halo-biphenyl-4-ylmethyl)-1,7'-dimethyl-2'-propyl-1H,3'H-[2,5']bibenzoimidazolyl, which can be further converted to organometallic compound and said organometallic compound is further reacted with formic acid derivative, such as N,N-dimethylformamide, alkylformiate or carbon dioxide to obtain telmisartan, is also described. Further described is use of in line analytics for monitoring the aforementioned reactions, process for preparing a pharmaceutical composition and/or dosage for, or use in preparing a medicament. |
| priorityDate | 2008-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 229.